TY - JOUR
T1 - Brain and cognitive functions in two groups of naïve HIV patients selected for a different plan of antiretroviral therapy
T2 - A qEEG study
AU - Babiloni, Claudio
AU - Pennica, Alfredo
AU - Capotosto, Paolo
AU - Onorati, Paolo
AU - Muratori, Chiara
AU - Ferracuti, Stefano
AU - Roma, Paolo
AU - Correr, Valentina
AU - Piccinni, Elisa
AU - Noce, Giuseppe
AU - Del Percio, Claudio
AU - Cordone, Susanna
AU - Limatola, Cristina
AU - Soricelli, Andrea
AU - Di Campli, Francesco
AU - Gianserra, Laura
AU - Ciullini, Lorenzo
AU - Aceti, Antonio
AU - Viscione, Magdalena
AU - Teti, Elisabetta
AU - Sarmati, L.
AU - Andreoni, M.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Objective Cortical sources of electroencephalographic (EEG) rhythms were investigated in two sub-populations of naïve HIV subjects, grouped based on clinical criteria to receive different combination anti-retroviral therapies (cARTs). These EEG sources were hypothesized to reflect beneficial effects of both regimes. Methods Eyes-closed resting state EEG data were collected in 19 (Group A) and 39 (Group B) naïve HIV subjects at baseline (i.e. pre-treatment; T0) and after 5 months of cART (T5). Compared with the Group A, the Group B was characterized by slightly worse serological parameters and higher cardiovascular risk. At T0, mean viral load (VL) and CD4 count were 87,694 copies/ml and 435 cells/μl in the Group A and 187,370 copies/ml and 331 cells/μl in the Group B. The EEG data were also collected in 50 matched control HIV-negative subjects. Cortical EEG sources were assessed by LORETA software. Results Compared to the Control Group, the HIV Groups showed lower alpha (8–12 Hz) source activity at T0 while the Group B also exhibited higher delta source activity. The treatment partially normalized alpha and delta source activity in the Group A and B, respectively, in association with improved VL, CD4, and cognitive functions. Conclusions Different cART regimens induced diverse beneficial effects in delta or alpha source activity in the two naïve HIV Groups. Significance These sources might unveil different neurophysiological effects of diverse cART on brain function in naïve HIV Groups as a function of clinical status and/or therapeutic compounds.
AB - Objective Cortical sources of electroencephalographic (EEG) rhythms were investigated in two sub-populations of naïve HIV subjects, grouped based on clinical criteria to receive different combination anti-retroviral therapies (cARTs). These EEG sources were hypothesized to reflect beneficial effects of both regimes. Methods Eyes-closed resting state EEG data were collected in 19 (Group A) and 39 (Group B) naïve HIV subjects at baseline (i.e. pre-treatment; T0) and after 5 months of cART (T5). Compared with the Group A, the Group B was characterized by slightly worse serological parameters and higher cardiovascular risk. At T0, mean viral load (VL) and CD4 count were 87,694 copies/ml and 435 cells/μl in the Group A and 187,370 copies/ml and 331 cells/μl in the Group B. The EEG data were also collected in 50 matched control HIV-negative subjects. Cortical EEG sources were assessed by LORETA software. Results Compared to the Control Group, the HIV Groups showed lower alpha (8–12 Hz) source activity at T0 while the Group B also exhibited higher delta source activity. The treatment partially normalized alpha and delta source activity in the Group A and B, respectively, in association with improved VL, CD4, and cognitive functions. Conclusions Different cART regimens induced diverse beneficial effects in delta or alpha source activity in the two naïve HIV Groups. Significance These sources might unveil different neurophysiological effects of diverse cART on brain function in naïve HIV Groups as a function of clinical status and/or therapeutic compounds.
KW - Alpha and delta rhythms
KW - Antiretroviral therapy (cART)
KW - CD4 counts
KW - Human immunodeficiency virus (HIV)
KW - LORETA
KW - Resting-state electroencephalography (EEG)
UR - http://www.scopus.com/inward/record.url?scp=84989936124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84989936124&partnerID=8YFLogxK
U2 - 10.1016/j.clinph.2016.09.001
DO - 10.1016/j.clinph.2016.09.001
M3 - Article
VL - 127
SP - 3455
EP - 3469
JO - Clinical Neurophysiology
JF - Clinical Neurophysiology
SN - 1388-2457
IS - 11
ER -